Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • ERS Guidelines
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • Peer reviewer login
  • Alerts
  • Subscriptions

The Finnish Allergy Programme 2008–2018 works

Tari Haahtela, Erkka Valovirta, Jean Bousquet, Mika Mäkelä and the Allergy Programme Steering Group
European Respiratory Journal 2017 49: 1700470; DOI: 10.1183/13993003.00470-2017
Tari Haahtela
1Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: tari.haahtela@haahtela.fi
Erkka Valovirta
2Dept of Lung Diseases and Clinical Allergology, University of Turku, and Allergy Clinic, Terveystalo, Turku, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean Bousquet
3MACVIA-France, Contre les Maladies Chroniques pour un Vieillissement Actif en France, European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France
4INSERM U 1168, VIMA: Ageing and chronic diseases Epidemiological and public health approaches, Villejuif, Université Versailles Saint-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mika Mäkelä
1Skin and Allergy Hospital, Helsinki University Hospital, University of Helsinki, Helsinki, Finland
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Revisiting the asthma and allergy paradigms has led to actions relevant to society and healthcare as a whole http://ow.ly/MBG530bPvd6

Introduction

In Finland (population 5,5 million), a 10-year national campaign to treat allergic diseases was initiated in 2008. It was carefully planned and based on consensus among experts [1–3] because the long-term strategy of allergen avoidance had not reduced the burden or stopped the “epidemic”. New insights into immune development in modern, urban societies have challenged conventional thinking. A public health programme has now been implemented, and an avoidance strategy was replaced with a tolerance strategy [4]. This course of action was supported by the Ministry of Social Affairs and Health and the National Institute for Health and Welfare.

The burden and the epidemic

In the early 1990s, asthma was recognised as an inflammatory condition with variable airflow limitation [5, 6]. The new paradigm emphasised first-line anti-inflammatory treatment [7], which was implemented in practice by the Finnish Asthma Programme 1994−2004. Step 1 involved cutting the disease burden for individual patients as well as for society by improving early diagnostics and medication [8–10]. The programme served as a model for others to follow [11, 12].

However, the main question remained: how to stop the epidemic? The asthma programme reduced the burden markedly but had no effect on the increased prevalence. Clearly, the true reasons for the increased incidence of allergy and asthma should be better understood in order to move from treatment to prevention. The Karelia Allergy Study, among others, provided some answers [13]. The contrast of prevalence was striking both among children and adults living in Finnish and more rural and traditional Russian Karelia. It seemed likely that the reasons for allergy increase were not so much the new risk factors, characteristic of a modern environment and lifestyle, but the loss of protective factors.

Non-communicable diseases (NCDs), which include allergy, have been increasing everywhere in urban environments. The human immune system seems to be experiencing an adaptation crisis which does not comply with the fast-changing lifestyle and living conditions. Effective gene–environment interaction is the key issue in tolerance development [14]. Reduced connection with natural environments and, for example, the increased use of processed food may have impoverished human microbiota (dysbiosis), caused immune dysfunction (poor tolerance) and led to inappropriate inflammatory responses. The manifested clinical disease is then largely dependent on individual genetic architecture.

Again, there was a place for a paradigm change. The Finnish Allergy Programme 2008–2018 was introduced to test new thinking in practice, and regarded the improvement in allergy health, including asthma health, as step 2.

Programme testing and implementation

The key messages of the programme are shown in Box 1. They targeted the general population, patients with allergies and asthma and their families, and public-health and patient organisations, as well as experts and authorities. The more specific goals and indicators for healthcare professionals were quantitative, such as that allergy diets should drop by 50% and asthma emergency visits by 40% within 10 years. Each of the six goals had specific tasks, tools and evaluation methods [1].

BOX 1 The Finnish Allergy Programme 2008–2018 messages for both healthcare professionals and lay-public; allergy health is promoted

Key messages

 Endorse health, not allergy

 Strengthen tolerance

 Adopt a new attitude to allergy, and avoid allergens only if mandatory

 Recognise and treat severe allergies early; prevent exacerbations

 Improve air quality; stop smoking

The relevance and acceptance of the messages were tested by email in 2008 among 744 asthma contact persons (response rate 71%; 38% were doctors, 62% nurses, 77% working in primary care) [15]. The messages were well received. For example, GPs scored strengthen tolerance as 9.1 on a scale from 4 to 10. However, allergy-management practice left much room for improvement, e.g. the availability of specific immunotherapy was poor (score 5.4).

The expert non-governmental organisation (NGO), the Finnish Lung Health Association (Filha), was responsible for the education of healthcare professionals (doctors, nurses, pharmacists, care-givers). The key issue was to improve allergen tolerance, and simple guidance was provided (table 1). Between 2008 and 2016, more than 20 000 professionals participated in the various learning activities. The lay-public has been targeted by three NGOs for: 1) allergy and asthma, 2) respiratory health, and 3) skin disorders. Patient organisations arranged regional education for their key personnel and peer workers; this had a major impact upon direct patient counselling and distribution of educational materials.

View this table:
  • View inline
  • View popup
TABLE 1

Practical advice for building and improving tolerance as well as preventing symptoms and exacerbations

Education continued also for the personnel of pharmacies, day-care centres, and schools. From 2009 to 2012, the Association of Finnish Pharmacies produced material and ran campaigns for allergic rhinitis and atopic eczema. The Association of Kindergarten Teachers in Finland planned a pilot campaign called “Go to nature!” for 2014–2015 in southern Karelia, incorporating various outdoor activities into the day-care routine. New guidelines for early childhood education are to be introduced throughout the country.

Contact-person network

Finland has 21 hospital districts (five university hospitals). Primary healthcare services are provided by about 250 primary care centres, including at least three times as many maternity and child health clinics and approximately 1000 units offering occupational health services, one-third of which are private.

The educational action plan took advantage of the contact-person network created early in the 1994–2004 asthma programme. At baseline, in 2008, about 1500 appointed asthma contact persons (doctors, nurses, pharmacists) were employed in the healthcare sector, originally recruited for the asthma programme. This network was reactivated and strengthened for the allergy campaign. The network has been complemented by some 200 nurses in maternity and child health clinics as well as in schools. Fourteen regional expert allergy groups have begun to coordinate the local implementation of new recommendations via educational activities.

Measuring outcomes

For outcome evaluation, the Finnish healthcare registers provided invaluable data sources – in particular, the hospital admission register of the National Institute for Health and Welfare and the drug reimbursement register of the Social Insurance Institution of Finland. For occupational diseases, Finland has strict legislation, and verified cases are registered by the Finnish Institute of Occupational Health.

The Finnish anaphylaxis register was established in 2000 at the Skin and Allergy Hospital of the Helsinki University Hospital [16]. Physicians (mostly allergists) from the whole country voluntarily report cases of severe allergic reactions independent of a causative agent. A one-page questionnaire for medical professionals is available on the internet.

Allergy and asthma costs in 2013 were analysed from all data sources in collaboration with government officials.

Are we reaching the goals?

The mid-term outcome is summarised in table 2. The burden of allergy and asthma has been further reduced since the beginning of the asthma programme [17]. In the 2000s, asthma emergency visits decreased by 46% (children 62%) and hospital days by 67%. According to a country-wide pharmacy barometer survey, self-reported asthma has become a milder disease or a better controlled disease [18]. At the start of the Finnish asthma programme in 1994, it was estimated that 20% of the patients had a severe (or uncontrolled) condition. This figure decreased to 10% in 2001 and to 4% in 2010. In 2016 this figure was 2.5% (P. Kauppi, J. Jantunen; unpublished, personal communication). Compared with the 2001 and 2010 cohorts, emergency visits during the previous year had dropped by 86% and hospitalisations by 88%. Asthma mortality has been very low: in 2006–2013, on average seven annual deaths (range 3–12) under the age of 60 years.

View this table:
  • View inline
  • View popup
TABLE 2

Six programme goals, indicators and main outcomes at 5 years

In 13 years (2000–2013), the number of emergency visits caused by anaphylaxis almost doubled from 297 to 582 cases. In children (1999–2011), hospitalisations due to allergic reactions increased (from 7.8 to 15.8 per 100 000 person-years), but the numbers were somewhat lower than those for Sweden [19]. The anaphylaxis campaign has improved awareness and explains much of the increase. Only a few anaphylaxis-related deaths per year occurred in 1996–2013, and no deaths occurred in children [20].

In the Helsinki capital region, 40 Finnish day-care centres were educated to follow simple pragmatic allergy guidelines [21]. In 2013–2015, the prevalence of allergy diets decreased 43%, from 7.6% to 4.3%. Parent-reported allergies to nuts, fruits and vegetables decreased among first graders in the first year of elementary schools [22].

In 2007–2013, verified occupational allergies (asthma, allergic rhinitis, allergic contact dermatitis) fell by 40%, as registered by the National Institute of Occupational Health. The reduction could not be explained by changes in the workforce.

In the first decade of the 2000s, the direct allergy and asthma costs, together with costs for disability pensions, fell by15% [17]. During the early years of the programme (2007−2013), these costs have fallen from €386 million to 367 million (−5%). Asthma costs decreased by 9% and comprised 63% of all costs.

Conclusions

There are no reports of nationwide, comprehensive public health programmes for allergic disorders that include set goals and systematic follow-up. The mid-term results of the ongoing Finnish campaign indicate that the burden of allergic conditions in that particular society has started to decline. Focusing on severe allergies and emphasising allergy health rather than mild problems has encouraged a more efficient use of healthcare resources. It also seems that prevalences are levelling off. However, it is too early to give credit to the programme for any biological changes in the population.

The outcome of the present real-life intervention, including all Finnish citizens, without effective controls is also open to criticism. This should not, however, prevent medical communities from taking reasonable action to improve public health, in this case lessening the disability and costs resulting from allergy and asthma. Inadequate allergy care seems to be a global problem and leads to delays in patient management and poor outcomes [23].

Revisiting the asthma and allergy paradigms has led to actions relevant to society and healthcare as a whole.

Disclosures

Supplementary Material

T. Haahtela ERJ-00470-2017_Haahtela

M. Mäkelä ERJ-00470-2017_Makela

E. Valovirta ERJ-00470-2017_Valovirta

Footnotes

  • The collaborating members of the Allergy Programme Steering Group are as follows: Peter Csonka, Matti Hannuksela, Leena von Hertzen, Juha Jantunen, Paula Kauppi, Krista Kauppinen, Tiina Laatikainen, Irmeli Lindström, Miika Linna, Sirpa Pajunen, Anna Pelkonen, Leena Petman, Mervi Puolanne, Ilkka Repo, Kimmo Saarinen, Alexander Salava, Johannes Savolainen, Erja Tommila, Tuula Vasankari.

  • Support statement: From 2008 to 2016, the Ministry of Welfare and Health allocated €60 000–65 000 annually for educational and coordinating work, which was organised by the Finnish Lung Health Association (Filha), an expert non-governmental organisation. Filha raised private funds of €50 000‒100 000 per year to carry out the education for more than 20 000 healthcare professionals in 2008–2016. For patient education and public communication, three non-governmental patient organisations together received, between 2011 and 2014, an annual payment of €200 000 from Finland's Slot Machine Association (RAY). The main purpose of the government-regulated RAY is to raise funds to promote health and welfare in Finland through gaming operations. Funding information for this article has been deposited with the Crossref Funder Registry.

  • Conflict of interest: Disclosures can be found alongside this article at erj.ersjournals.com

  • Received March 7, 2017.
  • Accepted March 8, 2017.
  • Copyright ©ERS 2017

References

  1. ↵
    1. Haahtela T,
    2. von Hertzen L,
    3. Mäkelä M, et al.
    Finnish Allergy Programme 2008–2018--time to act and change the course. Allergy 2008; 63: 634–645.
    OpenUrlCrossRefPubMedWeb of Science
    1. Bousquet J,
    2. Bieber T,
    3. Fokkens W, et al.
    In Allergy, ‘A new day has begun'. Allergy 2008; 63: 631–633.
    OpenUrlPubMed
  2. ↵
    1. Pelkonen AS,
    2. Kuitunen M,
    3. Dunder T, et al.
    Allergy in children: practical recommendations of the Finnish Allergy Programme 2008–2018 for prevention, diagnosis, and treatment. Pediatr Allergy Immunol 2012; 23: 103–116.
    OpenUrlPubMed
  3. ↵
    1. von Hertzen LC,
    2. Savolainen J,
    3. Hannuksela M, et al.
    Scientific rationale for the Finnish Allergy Programme 2008–2018: emphasis on prevention and endorsing tolerance. Allergy 2009; 64: 678–701.
    OpenUrlCrossRefPubMedWeb of Science
  4. ↵
    1. Laitinen LA,
    2. Heino M,
    3. Laitinen A, et al.
    Damage of the airway epithelium and bronchial reactivity in pa­tients with asthma. Am Rev Respir Dis 1985; 131: 599–606.
    OpenUrlPubMedWeb of Science
  5. ↵
    1. Bousquet J,
    2. Chanez P,
    3. Lacoste JY, et al.
    Eosinophilic inflammation in asthma. N Engl J Med 1990; 323: 1033–1039.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Haahtela T,
    2. Järvinen M,
    3. Kava T, et al.
    Comparison of a β2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325: 388–392.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Haahtela T,
    2. Tuomisto LE,
    3. Pietinalho A, et al.
    A 10 year asthma programme in Finland: major change for the better. Thorax 2006; 61: 663–670.
    OpenUrlAbstract/FREE Full Text
    1. Nermes M,
    2. Vanto T,
    3. Elenius V, et al.
    Lasten astman miniohjelma toteutuu tyydyttävästi [Adherence to national childhood asthma programme is satisfactory]. Finn Med J 2005; 60: 2805–2809.
    OpenUrl
  8. ↵
    1. Haahtela T,
    2. Herse F,
    3. Karjalainen J, et al.
    The Finnish experience to save asthma costs by improving care in 1987–2013. J Allergy Clin Immunol 2017; 139: 408–414.
    OpenUrl
  9. ↵
    1. Selroos O,
    2. Kupczyk M,
    3. Kuna P, et al.
    National and regional asthma programmes in Europe. Eur Respir Rev 2015; 24: 474–483.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Asher I,
    2. Haahtela T,
    3. Selroos O, et al.
    Global Asthma Network survey suggests more national asthma strategies could reduce burden of asthma. Allergol Immunopathol (Madr) 2017; 45: 105–114.
    OpenUrl
  11. ↵
    1. Haahtela T,
    2. Laatikainen T,
    3. Alenius H, et al.
    Hunt for the origin of allergy – comparing the Finnish and Russian Karelia. Clin Exp Allergy 2015; 45: 891–901.
    OpenUrlCrossRefPubMed
  12. ↵
    1. Garn H,
    2. Bahn S,
    3. Baune BT, et al.
    Current concepts in chronic inflammatory diseases: interactions between microbes, cellular metabolism, and inflammation. J Allergy Clin Immunol 2016; 138: 47–56.
    OpenUrl
  13. ↵
    1. Kauppi P,
    2. Kämäräinen J,
    3. Haahtela T
    . Kansallinen allergiaohjelma vaatii koulutusta ja työkaluja (Allergy Programme clearly necessary – training and tools needed). Finn Med J 2010; 43: 3515–3520.
    OpenUrl
  14. ↵
    1. Mäkinen-Kiljunen S,
    2. Haahtela T
    . Eight years of severe allergic reactions in Finland. A register-based report. World Allergy Organ J 2008; 1:184–189.
    OpenUrl
  15. ↵
    1. Haahtela T,
    2. Valovirta E,
    3. Hannuksela M, et al.
    Kansallinen allergiaohjelma puolivälissä – suunnan muutos tuo tuloksia [Finnish nationwide allergy programme at mid-term – Change of direction producing results]. Finn Med J 2015; 70: 2165–2172.
    OpenUrl
  16. ↵
    1. Kauppi P,
    2. Peura S,
    3. Salimäki J, et al.
    Reduced severity and improved control of self-reported asthma in Finland during 2001–2010. Asia Pac Allergy 2015; 5: 32–39.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Kivistö JE,
    2. Protudjer JL,
    3. Karjalainen J, et al.
    Hospitalizations due to allergic reactions in Finnish and Swedish children during 1999–2011. Allergy 2016; 71: 677–683.
    OpenUrl
  18. ↵
    1. Kivistö JE,
    2. Dunder T,
    3. Protudjer JL, et al.
    Adult but no pediatric anaphylaxis-related deaths in the Finnish population from 1996 to 2013. J Allergy Clin Immunol 2016; 138: 630–632.
    OpenUrl
  19. ↵
    1. Erkkola M,
    2. Saloheimo T,
    3. Hauta-alus H, et al.
    LILLA study group. Burden of allergy diets in Finnish day care reduced by change in practices. Allergy 2016; 71: 1453–1460.
    OpenUrl
  20. ↵
    1. Järvenpää J,
    2. Paassilta M,
    3. Salmivesi S, et al.
    Stability of parent reported food allergy in six and 7-year-old children: the first 5 years of the Finnish allergy programme. Acta Paediatr 2014; 103: 1297–1300.
    OpenUrl
  21. ↵
    1. Diwakar L,
    2. Cummins C,
    3. Lilford R, et al.
    Systematic review of pathways for the delivery of allergy services. BMJ Open 2017; 7: e012647.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
View this article with LENS
Vol 49 Issue 6 Table of Contents
European Respiratory Journal: 49 (6)
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Finnish Allergy Programme 2008–2018 works
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
The Finnish Allergy Programme 2008–2018 works
Tari Haahtela, Erkka Valovirta, Jean Bousquet, Mika Mäkelä
European Respiratory Journal Jun 2017, 49 (6) 1700470; DOI: 10.1183/13993003.00470-2017

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
The Finnish Allergy Programme 2008–2018 works
Tari Haahtela, Erkka Valovirta, Jean Bousquet, Mika Mäkelä
European Respiratory Journal Jun 2017, 49 (6) 1700470; DOI: 10.1183/13993003.00470-2017
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Introduction
    • The burden and the epidemic
    • Programme testing and implementation
    • Contact-person network
    • Measuring outcomes
    • Are we reaching the goals?
    • Conclusions
    • Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Subjects

  • Asthma and allergy
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Towards a better mucolytic
  • Relationship between gastroesophageal reflux and pulmonary fibrosis
  • Artificial intelligence: do we need it for lung function interpretation?
Show more Editorials

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society